Katrina Hazlett
Family · Denver, CONPI 1023764792
Payments from drug & device makers
Across 69 payments — averaging $22.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$196
- Viiv Healthcare Company$189
- Lilly USA, LLC$177
- Novo Nordisk$139
- AstraZeneca$114
- Amgen$84
- plus $679 from 19 others
What the payments were for
- Food & beverage$1,578100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 7 | $196 |
| Viiv Healthcare Company | 6 | $189 |
| Lilly USA, LLC | 9 | $177 |
| Novo Nordisk | 8 | $139 |
| AstraZeneca | 7 | $114 |
| Amgen | 4 | $84 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| Pfizer | 3 | $67 |
| Gilead | 3 | $64 |
| Sanofi-aventis U.S. LLC | 2 | $58 |
| Sumitomo Pharma America, Inc. | 1 | $56 |
| Bayer | 3 | $51 |
| Abiomed | 1 | $40 |
| Organon | 1 | $40 |
| Edwards Lifesciences | 1 | $33 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $30 |
| Amneal Pharmaceuticals LLC | 1 | $27 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $25 |
| Seqirus USA Inc | 1 | $21 |
| Electromed, Inc. | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| GSK | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Acella Pharmaceuticals, LLC | 1 | $15 |
How this compares
$1,578 in reported general payments places this provider in the 80th percentile of 2,182 family providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 20 | $581 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 16 | $170 |
| Atorvastatin Calcium | 13 | $121 |
Paid to pharmacies, not to this prescriber.
Other family in Denver
- Katie NadingDenver$28K
- Randall McDavidDenver$26K
- Kyle OdvodyDenver$24K
- Naser Kalani YazdDenver$15K
- Jennine StaffordDenver$15K
- Kara RobertsonDenver$10K
- Katherine RiedlerDenver$8K
- Laura GrahamLakewood$1.6M
- Corinne YoungColorado Springs$272K
- Margaret MachaffieColorado Springs$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.